John Newman
Stock Analyst at Canaccord Genuity
(1.47)
# 3,321
Out of 4,876 analysts
81
Total ratings
42.86%
Success rate
-11.51%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $1,152 → $850 | $521.00 | +63.15% | 16 | Apr 22, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $1.20 | +1,066.67% | 3 | Mar 14, 2025 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $106.14 | +61.52% | 8 | Mar 11, 2025 | |
| ATRA Atara Biotherapeutics | Maintains: Buy | $17 | $7.95 | +113.84% | 5 | Mar 11, 2025 | |
| MRKR Marker Therapeutics | Initiates: Buy | $8 | $1.46 | +447.95% | 1 | Mar 5, 2025 | |
| CADL Candel Therapeutics | Maintains: Buy | $20 → $25 | $5.03 | +397.02% | 2 | Feb 26, 2025 | |
| MCRB Seres Therapeutics | Maintains: Buy | $200 | $9.51 | +2,003.05% | 9 | Nov 14, 2024 | |
| DCTH Delcath Systems | Maintains: Buy | $21 | $14.05 | +49.47% | 1 | Oct 18, 2024 | |
| ACLX Arcellx | Maintains: Buy | $85 → $115 | $64.77 | +77.55% | 8 | Oct 17, 2024 | |
| ACET Adicet Bio | Maintains: Buy | $19 → $8 | $0.67 | +1,092.96% | 6 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 | $53.18 | +25.99% | 2 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $11.46 | +275.22% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.72 | +594.44% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $33.65 | +30.76% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $220 | $9.28 | +2,270.69% | 3 | Jun 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $15.34 | +147.72% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $3.87 | +597.67% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $8.63 | - | 1 | Sep 13, 2017 |
Regeneron Pharmaceuticals
Apr 22, 2025
Maintains: Buy
Price Target: $1,152 → $850
Current: $521.00
Upside: +63.15%
Allogene Therapeutics
Mar 14, 2025
Maintains: Buy
Price Target: $14
Current: $1.20
Upside: +1,066.67%
BioNTech SE
Mar 11, 2025
Maintains: Buy
Price Target: $171
Current: $106.14
Upside: +61.52%
Atara Biotherapeutics
Mar 11, 2025
Maintains: Buy
Price Target: $17
Current: $7.95
Upside: +113.84%
Marker Therapeutics
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.46
Upside: +447.95%
Candel Therapeutics
Feb 26, 2025
Maintains: Buy
Price Target: $20 → $25
Current: $5.03
Upside: +397.02%
Seres Therapeutics
Nov 14, 2024
Maintains: Buy
Price Target: $200
Current: $9.51
Upside: +2,003.05%
Delcath Systems
Oct 18, 2024
Maintains: Buy
Price Target: $21
Current: $14.05
Upside: +49.47%
Arcellx
Oct 17, 2024
Maintains: Buy
Price Target: $85 → $115
Current: $64.77
Upside: +77.55%
Adicet Bio
Sep 11, 2024
Maintains: Buy
Price Target: $19 → $8
Current: $0.67
Upside: +1,092.96%
Jul 25, 2024
Maintains: Buy
Price Target: $67
Current: $53.18
Upside: +25.99%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $11.46
Upside: +275.22%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.72
Upside: +594.44%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $33.65
Upside: +30.76%
Jun 13, 2018
Maintains: Buy
Price Target: $210 → $220
Current: $9.28
Upside: +2,270.69%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $15.34
Upside: +147.72%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $3.87
Upside: +597.67%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $8.63
Upside: -